119 related articles for article (PubMed ID: 24847649)
1. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
Welsch C
Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
4. Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL; Locarnini S; Beard MR
Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
[TBL] [Abstract][Full Text] [Related]
5. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
6. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
7. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
[TBL] [Abstract][Full Text] [Related]
8. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
[No Abstract] [Full Text] [Related]
9. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
10. Interferon-free strategies without a nucleoside/nucleotide analogue.
Welzel TM; Zeuzem S
Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
[TBL] [Abstract][Full Text] [Related]
11. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
12. A review of HCV protease inhibitors.
Chen KX; Njoroge FG
Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
[TBL] [Abstract][Full Text] [Related]
13. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
14. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
[TBL] [Abstract][Full Text] [Related]
15. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
16. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
[TBL] [Abstract][Full Text] [Related]
17. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
Li Z; Chen ZW; Ren H; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
[TBL] [Abstract][Full Text] [Related]
19. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
20. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
Colson P; Purgus R; Borentain P; Gérolami R
J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
